学科主题临床医学
Association between the HER2 Ile655Val polymorphism and response to trastuzumab in women with operable primary breast cancer
Han, X.1; Diao, L.1; Xu, Y.1; Xue, W.2; Ouyang, T.1; Li, J.1; Wang, T.1; Fan, Z.1; Fan, T.1; Lin, B.1; Xie, Y.1
关键词HER2 gene polymorphism trastuzumab breast cancer response
刊名ANNALS OF ONCOLOGY
2014-06-01
DOI10.1093/annonc/mdu111
25期:6页:1158-1164
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Oncology
研究领域[WOS]Oncology
关键词[WOS]ADJUVANT CHEMOTHERAPY ; GENETIC-POLYMORPHISM ; OPEN-LABEL ; CODON 655 ; RISK ; MULTICENTER ; ONCOGENE ; EFFICACY ; ANTIBODY ; THERAPY
英文摘要

Human epidermal growth factor receptor 2 (HER2) Ile655Val polymorphism may affect the efficacy of trastuzumab treatment of breast cancer.

HER2 Ile655Val polymorphism was determined in 4167 patients with primary breast cancer using a polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) assay. We investigated the associations between the HER2 Ile655Val polymorphism and clinical outcomes in women with HER2-negative breast cancer and with HER2-positive breast cancer who received trastuzumab or who did not.

At a median follow-up of 44 months, HER2 Ile655Val polymorphism was not significantly associated with survival either in the entire study population of 4167 patients or in 2976 HER2-negative breast cancer patients. Among 816 HER2-positive patients who received adjuvant chemotherapy and/or endocrine therapy without trastuzumab treatment, patients with the Val/Ile or the Val/Val genotype had a significantly worse disease-free survival (DFS) and distant DFS (DDFS) than those with the Ile/Ile genotype (DFS, adjusted hazard ratio [HR] 1.5; 95% confidence interval [CI] 1.0-2.3; P = 0.037; DDFS, adjusted HR 1.9; 95% CI 1.2-2.9 P = 0.005). In contrast, among 212 HER2-positive patients who received chemotherapy in combination with trastuzumab treatment, patients with the Val/Ile or the Val/Val genotype had a significantly better DFS and DDFS than those with the Ile/Ile genotype (5-year DFS, 100% versus 83%; P = 0.008; 5-year DDFS, 100% versus 89%; P = 0.031).

HER2 Ile655Val polymorphism affects the function of HER2 gene only restricted in HER2-positive breast cancers. HER2-positive breast cancer patients with the Val variant have an aggressive phenotype, but are sensitive to trastuzumab treatment.

语种英语
WOS记录号WOS:000337028100012
项目编号2013CB9 ; 30973436 ; 81071629
资助机构973 project ; program for Breast Cancer Tissue Bank of Beijing ; National Natural Science Foundation of China
引用统计
被引频次:22[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/63120
专题北京大学临床肿瘤学院_乳腺癌预防治疗中心
北京大学公共卫生学院_公共卫生学院
北京大学第三临床医学院_门诊部
北京大学第三临床医学院_眼科
北京大学临床肿瘤学院_乳腺中心实验室
作者单位1.Peking Univ, Breast Ctr, Canc Hosp & Inst, Key Lab Carcinogenesis & Translat Res,Minist Educ, Beijing 100142, Peoples R China
2.Peking Univ, Dept Pathol, Canc Hosp & Inst, Beijing 100142, Peoples R China
推荐引用方式
GB/T 7714
Han, X.,Diao, L.,Xu, Y.,et al. Association between the HER2 Ile655Val polymorphism and response to trastuzumab in women with operable primary breast cancer[J]. ANNALS OF ONCOLOGY,2014,25(6):1158-1164.
APA Han, X..,Diao, L..,Xu, Y..,Xue, W..,Ouyang, T..,...&Xie, Y..(2014).Association between the HER2 Ile655Val polymorphism and response to trastuzumab in women with operable primary breast cancer.ANNALS OF ONCOLOGY,25(6),1158-1164.
MLA Han, X.,et al."Association between the HER2 Ile655Val polymorphism and response to trastuzumab in women with operable primary breast cancer".ANNALS OF ONCOLOGY 25.6(2014):1158-1164.
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Han, X.]的文章
[Diao, L.]的文章
[Xu, Y.]的文章
百度学术
百度学术中相似的文章
[Han, X.]的文章
[Diao, L.]的文章
[Xu, Y.]的文章
必应学术
必应学术中相似的文章
[Han, X.]的文章
[Diao, L.]的文章
[Xu, Y.]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。